| Humalog pen (insulin lispro) / Eli Lilly |
NCT01334151: Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 13 | US | Insulin LISPRO, recombinant human insulin | Biodel | Diabetes Mellitus Type 1 | 08/11 | 08/11 | | |
NCT00652288: Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs |
|
|
| Completed | 1 | 36 | US | Insulin analogs (Lispro and Aspart), Humalog, Novolog, Insulin analogs (Aspart and Detemir), Insulin analogs (Lispro and Glargine) | Yale University | Diabetes Mellitus, Type I | 09/11 | 09/11 | | |
| Completed | 1 | 37 | US | TAK-329, Insulin, Insulin lispro, Humalog, Placebo | Takeda | Type 1 Diabetes Mellitus | 12/11 | 01/12 | | |
NCT01811849: Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 12 | RoW | Insulin LISPRO | Biodel | Type 1 Diabetes | 12/12 | 12/12 | | |
|
NCT02273258: A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 30 | Europe | SAR342434, Insulin Lispro | Sanofi | Type 1 Diabetes | 07/13 | 07/13 | | |
NCT02029924: A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 37 | Europe | BioChaperone insulin lispro, Humalog® | Adocia | Diabetes Mellitus Type 1 | 03/14 | 08/14 | | |
NCT02344992 / 2014-005028-92: Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal |
|
|
| Completed | 1 | 38 | Europe | BioChaperone insulin lispro, Humalog® | Adocia | Diabetes Mellitus Type 1 | 06/15 | 06/15 | | |
NCT02470637: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 30 | Europe | SAR439065, Afrezza Technosphere insulin, Insulin lispro, Humalog | Mannkind Corporation | Type 1 Diabetes Mellitus | 09/15 | 09/15 | | |
NCT02528396: To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 36 | Europe | BioChaperone insulin lispro, Humalog® | Adocia, Eli Lilly and Company | Type 1 Diabetes Mellitus | 12/15 | 12/15 | | |
NCT02603510: Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion |
|
|
| Completed | 1 | 27 | US | SAR342434, insulin lispro, Humalog | Sanofi | Type 1 Diabetes Mellitus | 04/16 | 04/16 | | |
NCT02500979: Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 34 | US | Pramlintide acetate, Pramlintide: SYMLIN, Placebo, Lispro insulin U-100, Humalog insulin lispro U-100, Regular insulin U-100, Humulin R; U-100 | AstraZeneca, Juvenile Diabetes Research Foundation | Type 1 Diabetes Mellitus | 08/16 | 08/16 | | |
NCT02562313: A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® |
|
|
| Completed | 1 | 80 | Europe | BioChaperone insulin lispro, Humalog® | Adocia, Eli Lilly and Company | Type 1 Diabetes Mellitus | 11/16 | 11/16 | | |
NCT02623478: A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps |
|
|
| Withdrawn | 1 | 0 | NA | Insulin Lispro, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 04/18 | 04/18 | | |
